USPTO serial 86442592
THE YB-1 COMPANY
Reviewed by CopyMark Law Group
Reg. 4835011Status 710
- Filing date
- Status date
- Registration date
- Oct 20, 2015
- Examiner
- MCMORROW, RONALD G
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with THE YB-1 COMPANY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Lisa V. Mueller
Lisa V. Mueller Michael Best & Friedrich LLP444 West Lake Street, Suite 3200Chicago, IL 60606UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical products for research use and for use in the manufacture of pharmaceuticals, namely, nucleic acids, vectors, plasmids, viruses, peptides and proteins, lipids, lipid coated proteins, lipid coated nucleic acids, lipid coated viruses, lipid coated vectors, lipid coated plasmids, antibodies, anticalines, aptamers, aptamers consisting essentially of L-nucleotides, short limiting RNA molecules without specific limitation to the number of nucleotides, antisense oligonucleotides, ribozymes, decoy oligonucleotides | SECTION 8 - CANCELLED | — |
| 005 | Pharmaceutical and veterinary preparations, namely, chemical products for medical and veterinary clinical use, namely, nucleic acids, vectors, plasmids, viruses, peptides and proteins, lipids, lipid coated proteins, lipid coated nucleic acids, lipid coated viruses, lipid coated vectors, lipid coated plasmids, antibodies, anticalines, aptamers, aptamers consisting essentially of L-nucleotides, short limiting RNA molecules without specific limitation to the number of nucleotides, antisense oligonucleotides, ribosomes, decoy oligonucleotides; slimming agents, appetite suppressants, acidosis therapeutics, analeptics, antihypoximics, analgesics, antirheumatic drugs, antihelmintics, antiallergics, anti-anemia drugs, antiarrhythmics, antibiotics, anti-infective agents, antidementics, nootropics, antidiabetics, antidotes, antiemetics, antivertiginosics, antiepileptics, antihemorrhagics, antifibrinolytics, hemostatics, antihypertonics, antihypoglycemics, antihypotonics, anticoagulants, antimycotics, antiparasitic agents, antiphlogistics, expectorants, agents for use in atherosclerosis, balneotherapeutics and preparations for heat therapy, beta receptor blocking agents, calcium channel blocking agents and inhibitors of the renin-angiotensin-system, broncholytics, antiasthmetics, cholagoguegics and biliary tract therapeutics, cholinergics, corticoids, dermatics, general purpose disinfectants, antiseptics, dietetic foods adapted for medical use, alimentary therapeutics, diagnostic preparations for medical and veterinary use, diuretics, preparations for the stimulation of blood circulation, fibrinolytics, geriatric agents for the treatment of stress and age-related diseases, geriatric nutritional supplements, agents for use in gout, agents for use in flu and in catarrhal fever, gynecological agents, hemorrhoid agents, hepatics, hypnotics, sedatives, cardiac therapeutics, agents for removal of dental stain, agents for reconstitution of gums, materials for dental fillings and for dental sealing purposes, corona agents, laxatives, antilipaemics, local anesthetics, neural therapeutics, gastro-intestinal agents, migraine agents, mineral supplements, mouth and pharyngeal therapeutics, muscle relaxants, narcotics, neuropathical agents and other neurotropic agents, ophthalmic preparations, agents for use in osteoporosis, calcium metabolism modifying agents, agents for use in Parkinson's Disease and other agents against disturbances of the extrapyramidal system, psychotropic agents, rhinologics, sinositic agents, roborants, thyroidal therapeutics, spasmolytics, inhibitors of thrombocyte aggregation, tuberculosis agents, altemants, urologics, venous agents, vitamins, cytostatics and other antineoplastic agents and protectives, homeopathic supplements; and Pharmaceutical and veterinary preparations in the nature of viruses, viruses for oncolysis, viruses for gene therapy, viruses for delivery of pharmaceutically active compounds, viruses for restoration of drug sensitivity, viruses for restoration of apoptosis, and viruses for cancer therapy, all for clinical use | SECTION 8 - CANCELLED | — |
| 009 | Scientific laboratory equipment, namely, photometers, mass spectrometers, ELISA readers, positron emission tomography (PET) scanners, thermocyclers, nuclear magnetic resonance (NMR) spectrometers, fluorescence-activated cell sorters, cell counters, blotting devices using electric, magnetic or capillary forces for material transfer | SECTION 8 - CANCELLED | — |
| 042 | Scientific and medical research services in biology, molecular biology, chemistry, biochemistry, genetics, molecular genetics, and pathology; scientific and medical research services for third parties, namely, determination of viral particles, determination and sequencing of viral genome, determination of drug resistance in samples, determination of radiation resistance in samples, design of viral vectors, design of plasmid vectors, design of viruses and in particular oncolytic viruses; scientific and medical research services, namely, design and performance of clinical trials | SECTION 8 - CANCELLED | — |
| 044 | Medical services featuring physicians and surgeons; veterinary services; medical services, namely, determination of individual disease risk, determination of individual cancer therapy, identifying patient groups treatable by oncolytic viruses, individual health care and managed health care services | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by XVir Therapeutics GmbH
- Other trademarks owned by XVir Therapeutics GmbH
- Other trademarks owned by XVir Therapeutics GmbH
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named THE YB-1 COMPANY
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 6, 2022 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Oct 20, 2020 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Apr 5, 2017 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 20, 2015 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 16, 2015 | DP1B | 1(B) BASIS DELETED; PROCEED TO REGISTRATION | — |
| Sep 15, 2015 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Aug 17, 2015 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Aug 17, 2015 | D1BR | TEAS DELETE 1(B) BASIS RECEIVED | — |
| Mar 17, 2015 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Mar 6, 2015 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 6, 2015 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 20, 2015 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 20, 2015 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 31, 2014 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 13, 2014 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Dec 13, 2014 | ALIE | ASSIGNED TO LIE | — |
| Dec 1, 2014 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 30, 2014 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 15, 2014 | MPMK | NOTICE OF PSEUDO MARK E-MAILED | — |
| Nov 13, 2014 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 6, 2014 | NWAP | NEW APPLICATION ENTERED | — |